自体细胞疗法rilparencel治疗糖尿病肾病的随机临床试验
这项多中心随机2期试验评估了自体细胞疗法rilparencel在糖尿病合并CKD患者中的疗效与安全性。结果显示,双侧肾脏注射与年eGFR下降斜率改善相关,且未报告产品相关严重不良事件。
要点
- rilparencel与年eGFR下降改善78%相关。
- 未报告产品相关严重不良事件。
- 介入操作耐受良好,安全性可接受。
核心结论
- 双侧肾脏注射rilparencel可能保护肾功能且安全性可接受。
主要发现
- 队列1注射前年eGFR斜率为-5.84(SEM 1.07),末次注射后为-1.27(SEM 1.36),差异4.57(95%CI 1.95至7.18)。
- 队列2注射前年eGFR斜率为-3.40(SEM 0.81),末次注射后为-1.71(SEM 1.04),差异1.70(95%CI -0.24至3.63)。
- 87次注射中,操作相关TEAE发生于16例,rilparencel相关TEAE发生于6例。
- 未报告产品相关严重不良事件及操作或产品相关死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Bilateral kidney injections with rilparencel was associated with a 78% improvement in the annual eGFR decline in kidney function. There were no serious adverse events related to rilparencel therapy. The interventional procedures were well tolerated and had an acceptable safety profile. BACKGROUND: Despite new treatments to delay disease progression in patients with diabetes and CKD, many patients continue to lose kidney function and progress to kidney failure. Additional therapeutic strategies, perhaps targeting multiple deleterious pathways, are necessary to preserve kidney function in patients with advanced CKD. METHODS: A multicenter, randomized, phase 2 clinical trial (NCT05018416) assessed rilparencel (an autologous cell therapy composed of cells obtained by kidney biopsy), in participants with diabetes and estimated glomerular filtration rate (eGFR) 20–50 ml/min per 1.73 m2. Participants were randomized 1:1 to two cohorts. Cohort 1 received two rilparencel injections percutaneously into the kidney cortex, 3 months apart, one in each kidney. Cohort 2 received one injection and a second injection only upon a sustained decline in eGFR or increase in urinary albumin creatinine ratio. Participants were followed up to 18 months after their last injection. The primary efficacy end point was change in eGFR slope from the preinjection period to the period after the last injection. The primary safety end point was the percentage of participants with procedure or rilparencel-related treatment emergent adverse events (TEAEs). RESULTS: Fifty-three participants were randomized and 49 received at least one injection. In Cohort 1, annual eGFR slope (ml/min per 1.73 m2/year) in the preinjection period was -5.84 (SEM 1.07) versus −1.27 (SEM 1.36) in the period after the last injection (difference 4.57 [95% confidence interval, 1.95 to 7.18]). In Cohort 2, annual eGFR slope in the pre-injection period was −3.40 (SEM 0.81) versus −1.71 (SEM 1.04) in the period after the last injection (difference 1.70 [95% confidence interval, −0.24 to 3.63]). No interactions were observed across multiple predefined baseline subgroups. Of 87 injections, procedure-related TEAEs occurred in 16 participants and rilparencel-related TEAEs occurred in six participants. No product-related serious adverse events and no procedure-related or product-related deaths were reported. CONCLUSIONS: Bilateral kidney injection of rilparencel may preserve kidney function with an acceptable safety profile. A multicenter, phase 3, randomized, sham-controlled study is ongoing.
引用
- Čižman B, Butler EL, Stavas J, et al. A Randomized Clinical Trial of Kidney Autologous Cell Therapy in Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2026. PMID: 41481370. doi:10.2215/CJN.0000000969
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。